BeyondSpring Inc Dossier - Source-backed chat

BeyondSpring Inc

BYSINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.43

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.77Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $31.7M

Enterprise Value $29.4M

Shares Outstanding 41.1M diluted

Next Earnings Date15 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing its lead asset, Plinabulin, for the treatment of non-small cell lung cancer (NSCLC). The company is transitioning through a critical execution phase, highlighted by a leadership change effective July 1, 2026, to focus on completing the global Phase 3 DUBLIN-4 confirmatory trial. While Plinabulin has demonstrated strong overall survival benefits in the DUBLIN-3 study, the company's highly constrained balance sheet—with only $7.9 million in cash and short-term investments as of March 31, 2026, and a widening shareholders' deficit of $30.4 million—presents significant going-concern and dilution risks. Investors should maintain a Hold position until clinical execution on DUBLIN-4 accelerates or additional non-dilutive financing is secured.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.3020%

The company faces severe liquidity constraints, failing to secure additional capital to fund the DUBLIN-4 trial, which leads to clinical delays. Delisting from NASDAQ occurs due to failure to meet continued listing requirements, severely impacting stock liquidity and driving down valuation.

Base CaseCentral scenario

$1.7055%

BeyondSpring slowly advances the DUBLIN-4 trial utilizing its clinical infrastructure in China. The company manages its cash burn through disciplined spending and potential partial sales of its remaining SEED Therapeutics equity. The stock remains range-bound as the market awaits concrete clinical trial enrollment updates and regulatory clarity.

Bull CaseUpside scenario

$5.0025%

The global Phase 3 DUBLIN-4 confirmatory trial succeeds rapidly, demonstrating strong overall survival in EGFR wild-type non-squamous NSCLC patients. This leads to FDA approval of Plinabulin, triggering a Hatch-Waxman patent term extension to 2041. Additionally, SEED Therapeutics' molecular glue platform achieves major clinical milestones, driving substantial valuation increases for BeyondSpring's remaining equity stake.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong clinical foundation with Plinabulin's DUBLIN-3 Phase 3 results published in The Lancet Respiratory Medicine, showing doubled 2- and 3-year survival rates.
Strategic leadership transition effective July 1, 2026, bringing in Min Qiu as CEO to focus specifically on executing the DUBLIN-4 trial and leveraging deep Chinese clinical networks.
Valuable equity interest in SEED Therapeutics (currently ~38%), which recently advanced its lead RBM39 molecular glue degrader ST-01156 into Phase 1 trials.
Robust intellectual property portfolio with U.S. composition-of-matter patents extending to 2036, and potential extension to 2041 upon FDA approval.

Key Investment Risks

Severe liquidity risk with only $7.9 million in cash and short-term investments as of March 31, 2026, against a quarterly burn rate.
Significant balance sheet weakness, with a total shareholders' deficit of $30.4 million as of March 31, 2026.
High clinical and regulatory dependency on the success of the DUBLIN-4 confirmatory trial, with any delays or negative outcomes severely impacting the company's viability.
Risk of NASDAQ delisting if the company fails to meet continued listing requirements, including minimum bid price or equity thresholds.

Thesis Invalidation Triggers

Failure to enroll patients in the DUBLIN-4 trial according to the projected timeline.
Inability to secure additional financing or complete planned equity sales of SEED Therapeutics, leading to a going-concern crisis.
Official notification of NASDAQ delisting proceedings without a viable path to compliance.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.